Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisEric L. Simpson, Marius Ardeleanu, Thomas Bieber et al.|New England Journal of Medicine|2016Cited by 2k
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic DermatitisEric L. Simpson, Ashish Bansal, Bolanle Akinlade et al.|JAMA Dermatology|2019Cited by 505
Dupilumab in Adults and Adolescents with Eosinophilic EsophagitisEvan S. Dellon, Arsalan Shabbir, Marc E. Rothenberg et al.|New England Journal of Medicine|2022Cited by 452
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil CountsSurya P. Bhatt, Raolat M. Abdulai, Klaus F. Rabe et al.|New England Journal of Medicine|2023Cited by 452
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic EsophagitisIkuo Hirano, Allen Radin, Evan S. Dellon et al.|Gastroenterology|2019Cited by 448